About 2,323 results

ALLMedicine™ Neuro-oncology Center

Research & Reviews  747 results

A practical guide to neuro-oncology fellowship.
https://doi.org/10.1007/s11060-021-03897-2 10.1093/neuonc/noaa155 10.1093/neuonc/noab106 10.1093/nop/npaa055 10.6004/jnccn.2008.0037 10.1056/NEJM190101171440304 10.1111/j.1365-2923.2010.03628.x
Journal of Neuro-oncology; Gonzalez Castro LN, Forst DA et. al.

Dec 3rd, 2021 - Neuro-oncology is a growing, interdisciplinary field at the intersection of neurology and oncology, devoted to the care of patients with central nervous system tumors and neurologic complications of cancer, and collaboratively interfacing with neu...

Liquid biopsy in neuro-oncology: are we finally there?
Annals of Oncology : Official Journal of the European Soc... Fontanilles M, Sanson M et. al.

Nov 25th, 2021 - Liquid biopsy in neuro-oncology: are we finally there?|2021|Fontanilles M,Sanson M,Touat M,|

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Nov 25th, 2021 - PRIMARY OBJECTIVES: I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT. II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters ...

Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COV...
Advanced Drug Delivery Reviews; Ljubimov VA, Ramesh A et. al.

Nov 23rd, 2021 - Neurosurgery as one of the most technologically demanding medical fields rapidly adapts the newest developments from multiple scientific disciplines for treating brain tumors. Despite half a century of clinical trials, survival for brain primary t...

Consensus core clinical data elements for meningiomas.
Neuro-oncology Nassiri F, Wang JZ et. al.

Nov 19th, 2021 - With increasing molecular analyses of meningiomas, there is a need to harmonize language used to capture clinical data across centers to ensure that molecular alterations are appropriately linked to clinical variables of interest. Here the Interna...

see more →

Guidelines  9 results

Clinical practice guidelines for the management of adult diffuse gliomas.
Cancer Letters; Jiang T, Nam DH et. al.

Nov 10th, 2020 - To follow the revision of the fourth edition of WHO classification and the recent progress on the management of diffuse gliomas, the joint guideline committee of Chinese Glioma Cooperative Group (CGCG), Society for Neuro-Oncology of China (SNO-Chi...

Natura non facit saltus: a phase 2 proposal to manage brain tumors cases from the Neuro...
Journal of Neurosurgical Sciences; Angileri FF, Sabatino G et. al.

Jun 12th, 2020 - The Coronavirus (COVID-19) pandemic has fast spread throughout the world in more than 200 countries, resulting in the need for a de-prioritization of elective medical care to face the demands of the global health crisis. Although the acute and cat...

Response assessment in paediatric high-grade glioma: recommendations from the Response ...
The Lancet. Oncology; Erker C, Tamrazi B et. al.

Jun 6th, 2020 - Response criteria for paediatric high-grade glioma vary historically and across different cooperative groups. The Response Assessment in Neuro-Oncology working group developed response criteria for adult high-grade glioma, but these were not creat...

Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. ...
Journal of Neurosurgical Sciences; Rudà R, Angileri FF et. al.

Apr 30th, 2020 - In 2018, the SINch (Italian Society of Neurosurgery) Neuro-Oncology Section, AINO (Italian Association of Neuro-Oncology) and SIN (Italian Association of Neurology) Neuro-Oncology Section formed a collaborative Task Force to look at the diagnosis ...

EANO guideline on the diagnosis and treatment of vestibular schwannoma.
Neuro-oncology Goldbrunner R, Weller M et. al.

Sep 11th, 2019 - The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms. Therefore, the vestibular schwannoma task force of the European Association of Neuro-Oncology assessed the data...

see more →

Clinicaltrials.gov  42 results

FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Nov 25th, 2021 - PRIMARY OBJECTIVES: I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT. II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters ...

CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Nov 10th, 2021 - PRIMARY OBJECTIVE: I. Determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of CB-839 hydrochloride (HCl) (telaglenastat) when combined with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagn...

Medical Marijuana in the Pediatric Central Nervous System Tumor Population

Nov 10th, 2021 - Children's Hospital Colorado (CHCO) Center for Cancer and Blood Disorders (CCBD) is a national leader in pediatric cancer therapy. The CHCO Neuro-Oncology program treats more that 90% of Coloradan children with Central Nervous System (CNS) tumors ...

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Nov 9th, 2021 - PRIMARY OBJECTIVE: I. To compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between participants randomized to the triplet combination of encorafenib + binimetinib + nivolumab versus the doublet c...

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma

Nov 9th, 2021 - This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). Relapsed participants will receive an individualized treatment recommendation including up to four FDA-approved drugs based on the results...

see more →

News  129 results

Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future Perspectives

Oct 6th, 2021 - Sylvia C. Eisele, MD, PhD Abstract Immunotherapies have emerged as new and promising treatment strategies against a variety of cancers and are currently intensely investigated in many tumors, including malignant gliomas. Glioblastomas...

Reardon on Promising Results With Rindopepimut in Brain Cancer

Oct 6th, 2021 - David Reardon, MD Rindopepimut is the first immunotherapy to have shown a survival benefit in brain cancers, specifically glioblastoma, explains David Reardon, MD. Data showcasing the agent's clinical activity were reported from the phase II ran...

Dr. Reardon on Efficacy/Safety of Immunotherapy Combination in Glioblastoma

Oct 6th, 2021 - David A. Reardon, MD, clinical director, Neuro-Oncology, Dana-Farber Cancer Institute, discusses the safety and efficacy of an immunotherapy combination for patients with glioblastoma. He presented phase II data at the 2018 ASCO Annual Meeting. T...

Early Potential Seen With Immunotherapy in Glioblastoma, But Questions Remain

Oct 6th, 2021 - David Reardon, MD Initial findings from clinical trials separately exploring the safety and efficacy of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as potential treatments for patients with glioblastoma are promising, acc...

Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

Oct 6th, 2021 - Adilia Hormigo, MD, PhD, director of the Neuro-Oncology Program, professor of neurology, neurosurgery, and medicine, Tisch Cancer Institute, Mount Sinai Hospital, discusses the current treatment landscape of glioblastoma. Glioblastoma is a grad...

see more →

Patient Education  2 results see all →